会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Variant of ciliary neurotrophic factor and DNA encoding the variant
    • 睫状神经营养因子的变体和编码变体的DNA
    • US06660467B1
    • 2003-12-09
    • US09381393
    • 1999-09-20
    • Isabelle GloaguenAnnalise Di MarcoAnna De MartisRalph LauferIsabella Saggio
    • Isabelle GloaguenAnnalise Di MarcoAnna De MartisRalph LauferIsabella Saggio
    • C12N500
    • C07K14/475A61K38/00
    • The subject of the present invention are variants of ciliary neurotrophic factor with enhanced receptor selectivity (CNTFR), useful for the treatment of diseases and disorders including motor neuron diseases and muscle degenerative diseases. Another subject of the invention is to provide a method for identifying the above mentioned CNTF variants. The hCNTF variants with the amino acid substitutions in accordance with the present invention, have a reduced ability, as compared to the human CNTF, to elicit biological effects through soluble CNTFR, without affecting its ability to activate membrane-bound neuronal CNTF receptors, thereby improving its therapeutic properties. FIG. 1 shows the reduced CNTFR binding affinity of a CNTF variant according to the invention (IA-CNTF; SEQ ID NO: 2). It is evident that the binding affinity of this variant to the CNTFR is reduced as compared to the wild-type human CNTF molecule.
    • 本发明的主题是具有增强的受体选择性(CNTFR)的睫状神经营养因子的变体,其可用于治疗疾病和病症,包括运动神经元疾病和肌肉退行性疾病。 本发明的另一主题是提供一种鉴定上述CNTF变体的方法。 根据本发明具有氨基酸取代的hCNTF变体与人CNTF相比具有降低的能力,通过可溶性CNTFR引起生物学效应,而不影响其活化膜结合的神经元CNTF受体的能力,从而改善 其治疗性质。 图。 图1显示根据本发明的CNTF变体(IA-CNTF; SEQ ID NO:2)的CNTFR结合亲和力降低。 显然,与野生型人CNTF分子相比,该变体与CNTFR的结合亲和力降低。